Stockreport

Cartesian reports positive results from Phase IIb myasthenia gravis trial [Yahoo! Finance]

Cartesian Therapeutics, Inc.  (RNAC) 
PDF chimeric antigen receptor T-cell therapy (mRNA CAR-T), in patients with generalised myasthenia gravis (MG). The double-blind, crossover, placebo-controlled trial invol [Read more]